



Contact: Julie Bryant  
VP Business Development and Marketing  
GeneGo, Inc.  
(858) 756 7996  
julie@genego.com

## **BERLEX SIGNS LICENSE AGREEMENT WITH GENEGO**

**St. Joseph, Michigan, March 13th, 2006** – GeneGo, Inc., a leading provider of software and databases for systems biology, today announced that it has entered into a licensing agreement with Berlex, Inc., a U.S. affiliate of Schering AG, Germany (NYSE: SHR, FSE: SCH), for MetaCore. The license provides researchers at Berlex and its German parent company with use of the MetaCore platform for analysis of gene expression, proteomic, metabolic and other high-throughput data in multiple therapeutic areas, including oncology, and in diagnostic applications.

"We are very pleased to bring MetaCore into our research," said Hugh Salamon, senior computational biologist, Berlex. "It is essential to exploit curation of scientific findings given the large body of knowledge relevant to therapeutic research. GeneGo is providing us with an important view of current knowledge of mammalian signaling, metabolism, drugs and diseases through the MetaCore platform."

"We are very pleased that researchers at Berlex Biosciences, the US research center for Berlex, will be using MetaCore and to have the company as a GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo. "Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore as a versatile, multi-purpose data mining tool applicable in diverse life science projects

### **About GeneGo**

GeneGo develops systems biology technology for life science research. The original computational platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, siRNA and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 2.5, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug<sup>TM</sup> is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase<sup>TM</sup> represents the knowledge base for MetaCore. For more information, please visit the company's web site at [www.genego.com](http://www.genego.com).

**MetaCore<sup>TM</sup>, MetaBase<sup>TM</sup> and MetaDrug<sup>TM</sup> are trademarks of GeneGo, Inc.**